Steven AR Murphy: The Risk of Pulmonary Embolism in IV Stem Cell Therapy
Steven AR Murphy, Medical Director at Concierge Medical Associates, reposted from World Mitochondria Society on LinkedIn:
“IV infusion of mesenchymal stem cells resulting in mitochondrial aggregation and pulmonary embolism! That is the risk of IV stem cell therapy. World Mitochondria Society highlights this REAL risk. Concierge Medical Associates and I work with teams all over the globe to educate about the potential of mitochondrial transfer and about the risks of PE from these therapies. I’m so glad the science is being presented in Germany! We need a meeting in the USA now before we see some seriously Wild West risks and poor outcomes! p.s. that autologous MSC or PRP you received, that’s a mitochondrial transfer….”
Quoting World Mitochondria Society‘s post:
“Development of Mitochondria-Based Therapeutic Strategies for Disease Treatment. Prof. Kosuke Kusamori (Tokyo University of Science, Japan) presented innovative research advancing the field of mitochondrial transplantation and organelle-based therapy. His team investigated the use of mitochondria isolated from mesenchymal stromal cells (C3H10T1/2) as bioenergetic therapeutics capable of restoring damaged tissues. These mitochondria demonstrated strong antioxidant, proliferative, and cytoprotective properties, particularly in models of acute liver injury.
However, Prof. Kusamori identified a critical barrier to clinical translation: mitochondrial aggregation following systemic administration, which can cause pulmonary embolism. His group developed a proprietary anti-aggregation modification, allowing for safe intravenous delivery, targeted accumulation in the liver, and significant reduction of hepatic injury markers (ALT, AST).
This breakthrough demonstrates that controlling the physicochemical properties of isolated mitochondria is essential to unlock their therapeutic potential, a decisive step toward safe and effective mitochondria-based treatments for inflammatory and ischemic diseases.
Thanks for these excellent study.”
Stay updated with Hemostasis Today.
-
Oct 11, 2026, 16:57Shiny K. Kajal: Japan Advances Artificial Blood via Haemoglobin Vesicles Trials
-
Oct 11, 2026, 16:45Luca Scarcia: Rescue Stenting Superior When Posterior Circulation Thrombectomy Fails
-
Oct 11, 2026, 16:27Giuseppe Bellelli: Reevaluating Anticoagulation Net Benefit in Frail Older Adults
-
Oct 11, 2026, 16:17Johnathan Whetstine: How Does MYC Go From 2 Copies to an Amplified Oncogene?
-
Oct 11, 2026, 16:03Parth Parmar: Practical Guidelines for Managing Venous Thromboembolism
-
Oct 11, 2026, 15:31Muhammad Alvi: CASPR Study Explores Treatment Response Across ESUS Phenotypes
-
Oct 11, 2026, 15:15Thalassaemia International Federation Joins ASCAT 2026 to Advance Sickle Cell and Thalassaemia Care
-
Oct 11, 2026, 15:14Challenges and Perspectives on Gene Therapy in Hemophilia A – Seminars in Thrombosis and Hemostasis
-
Oct 11, 2026, 15:07Neysa Rahardjo: Platelet Estimation Pitfalls and Discrepancy Resolution